Imunon, Inc. IMNN
Last close
1.24
2026-10-23
Market cap
$6.9M
2026-06-30 share count
52-week range
0.96 - 4.90
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-6.83
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | — |
| R&D | $7.8M | $11.6M | $11.3M | $11.7M | $10.6M | $11.3M | $13.1M | $11.9M | $13.1M | $14.6M |
| SG&A | $6.9M | $7.5M | $9.7M | $13.7M | $10.9M | $7.6M | $8.0M | $9.7M | $5.9M | $6.5M |
| Total operating expenses | $14.7M | $19.1M | $21.0M | $25.4M | $21.5M | $19.0M | $21.1M | $21.6M | $19.0M | $21.1M |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M | -$21.0M | -$18.5M | -$20.6M | -$21.1M | -$18.5M | -$20.6M |
| Interest expense | — | — | $197.1K | $5.0M | $569.9K | $1.3M | — | — | — | — |
| Pre-tax income | $14.5M | $18.6M | -$20.8M | -$37.5M | -$22.2M | -$23.3M | -$18.7M | -$22.3M | -$20.4M | — |
| Income tax | — | — | $1.3M | $1.6M | $1.4M | $1.8M | $1.8M | $10.4M | — | — |
| Net income | $14.5M | -$18.6M | -$19.5M | -$35.9M | -$20.8M | -$21.5M | -$16.9M | -$11.9M | -$20.4M | -$22.1M |
| EPS, basic | -6.83 | -16.94 | -2.16 | -5.03 | -3.83 | — | — | — | — | — |
| EPS, diluted | -6.83 | -16.94 | -2.16 | -5.03 | -3.83 | -10.08 | -0.77 | -0.68 | -2.72 | -11.89 |
| Shares, diluted (wtd. avg.) | 2.1M | 1.1M | 9.0M | 7.1M | 5.4M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.8M | $5.9M | $5.8M | $11.5M | $19.6M | $17.2M | $6.9M | $13.4M | $11.4M | $2.6M |
| Short-term investments | — | — | $9.9M | $21.2M | $29.8M | — | $7.9M | $14.2M | $12.7M | $1.7M |
| Total current assets | $10.7M | $8.0M | $18.2M | $36.8M | $51.9M | $18.8M | $16.2M | $28.1M | $24.3M | $4.5M |
| Property, plant and equipment | $529.9K | $541.3K | $751.9K | $548.3K | $477.0K | $294.6K | $405.4K | $184.6K | $175.8K | $462.8K |
| Goodwill | — | — | — | — | — | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Other intangibles | — | — | — | — | — | $113.7K | $341.0K | $568.3K | $795.6K | $1.0M |
| Total assets | $12.3M | $9.7M | $21.9M | $44.0M | $74.0M | $37.5M | $38.3M | $46.9M | $47.5M | $30.8M |
| Accounts payable | — | — | $3.5M | $3.6M | $2.5M | $2.2M | $2.9M | $3.0M | $3.4M | $2.9M |
| Total current liabilities | $4.6M | $4.8M | $7.4M | $10.0M | $6.8M | $6.8M | $7.9M | $6.1M | $6.2M | $8.4M |
| Long-term debt | — | — | — | $6.0M | $5.9M | $5.1M | $9.8M | $9.4M | — | — |
| Total liabilities | $5.2M | $5.5M | $8.5M | $14.6M | $18.3M | $18.9M | $23.7M | $26.0M | $20.8M | $24.1M |
| Retained earnings | -$421.3M | -$406.8M | -$388.2M | -$368.7M | -$332.8M | -$312.0M | -$290.5M | -$273.7M | -$261.8M | -$241.4M |
| Total equity | $7.1M | $4.2M | $13.4M | $29.3M | $55.8M | $18.6M | $14.6M | $20.9M | $26.7M | $6.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.9M | -$18.9M | -$19.0M | -$23.1M | -$16.2M | -$15.6M | -$20.3M | -$7.0M | -$16.6M | -$18.4M |
| Depreciation and amortisation | $291.9K | $240.2K | $248.2K | $196.5K | $702.9K | $741.5K | $721.7K | $356.9K | $553.0K | $1.0M |
| Stock-based compensation | $127.4K | $477.3K | $759.0K | $2.7M | $3.8M | $1.9M | $2.3M | $4.6M | $1.1M | $1.5M |
| Capital expenditure | $280.6K | $29.5K | $451.8K | $267.8K | $311.6K | $19.1K | $349.2K | $138.4K | $38.6K | $62.5K |
| Investing cash flow | -$280.6K | $9.8M | $11.0M | $8.3M | -$30.1M | $7.9M | $5.9M | -$1.6M | -$11.0M | $9.1M |
| Financing cash flow | $17.1M | $9.1M | -$3.6M | $6.7M | $54.8M | $18.0M | $7.8M | $10.6M | $36.5M | $2.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020999.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$22.1M | -$20.4M | -$11.9M | -$16.9M | -$21.5M | -$20.8M | -$35.9M | -$19.5M | -$18.6M | $14.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |